SCHEMBL588222

SCHEMBL588222

Clc1ccc(CNc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
RECQL P46063 1/20 0.59
RAB9A P51151 1/20 0.59
FFAR1 O14842 2/20 0.59
CYP3A4 P08684 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
HPGD P15428 2/20 0.56
ALOX12 P18054 1/20 0.56
CNR2 P34972 1/20 0.56
KDM4E B2RXH2 2/20 0.55
PTPRF P10586 1/20 0.55
PTPN2 P17706 1/20 0.55
PTPN1 P18031 1/20 0.55
PTPN11 Q06124 1/20 0.55
HDAC1 Q13547 1/20 0.54
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL587762 0.91 HTT (0.64) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL10945837 0.89 MEN1 (0.71) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL11512612 0.89 MEN1 (0.71) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL2065031 0.89 CYP1A2 (0.69) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL11509661 0.88 FFAR1 (0.63) MEN1KMT2ACYP1A2CYP2C9CYP2C19
N-Benzylaniline SCHEMBL7840 0.84 HTT (0.71) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL22628164 0.84 HTT (0.71) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL632349 0.82 EGFR (0.59) MEN1KMT2ACYP1A2CYP2C9CYP2C19
N-Benzylaniline SCHEMBL3602124 0.81 HTT (0.68) MEN1KMT2ACYP1A2CYP2C9CYP2C19
N-Benzylaniline SCHEMBL357137 0.81 HTT (0.68) MEN1KMT2ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101475-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ANTIHISTAMINIC DRUGS VIA A NOVEL CARBAMATE INTERMEDIATE JUBILANT LIFE SCIENCES LIMITED (IN) 2012-08-02 WO claimed
US-7851627-B2 Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-12-14 US claimed
US-20090221823-A1 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2009-09-03 US claimed
EP-1963296-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) 2008-09-03 EP claimed
WO-2007066163-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) 2007-06-14 WO claimed
CN-119701982-A Application of niobium oxide supported copper catalyst in synthesis of secondary amine or derivative thereof from aromatic nitro compound and benzyl alcohol compound 兰州大学 2025-03-28 CN disclosed
CN-119318958-A Zr(OH)4Preparation of Cu-supported bifunctional catalyst and application of Cu-supported bifunctional catalyst in catalytic synthesis of N-benzyl aniline compound 兰州大学 2025-01-17 CN disclosed
CN-119303575-A Novel Cu+Zr (OH)4Application of physical mixed catalyst in catalytic synthesis of N-benzylidene aniline or derivative thereof 兰州大学 2025-01-14 CN disclosed
CN-114409493-B Method for synthesizing 9-aryl fluorene compound 浙江工业大学 2024-02-23 CN disclosed
CN-112409188-B Method for synthesizing N-alkylamine 南京理工大学 2023-05-05 CN disclosed
CN-114409493-A Method for synthesizing 9-aryl fluorene compound 浙江工业大学 2022-04-29 CN disclosed
CN-109046463-B Bidentate aza-carbene-manganese catalyst, preparation method and alkylation synthesis application thereof 中山大学 2021-05-04 CN disclosed
US-7851627-B2 Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-12-14 US disclosed
US-20090221823-A1 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2009-09-03 US disclosed
EP-1963296-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) 2008-09-03 EP disclosed
WO-2007066163-A2 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) 2007-06-14 WO disclosed
WO-2004075847-A2 METHODS AND COMPOUNDS FOR THE TREATMENT OF Aß­ ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS MESSAGE PHARMACEUTICALS, INC. (US) 2004-09-10 WO disclosed
EP-0002721-B1 PROCESS FOR PREPARING HYDRAZINES BAYER AG (DE) 1981-09-02 EP disclosed
EP-0002721-A2 Process for preparing hydrazines BAYER AG (DE) 1979-07-11 EP disclosed
US-4152452-A N-BENZYLANILINE AND DERIVATIVES WILLIAM H. RORER, INC. (US) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221823-A1 OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES HRH4, HRH1, HRH2 MEN1 4160/4885KMT2A 287/4885CYP1A2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.